GLP-1 Market
LLY $1306.69 ▲ +2.8% NVO $39.43 ▲ +0.9% PFE $30.42 ▲ +1.9% VKTX $25.83 ▼ -2.1% KLRA $13.27 ▲ +2.7% GPCR $21.93 ▼ -0.4% RHHBY $59.62 ▲ +0.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Pegtibatinase

Company
Travere Therapeutics, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 23, 2026

Find a Clinical Trial Near Me

See recruiting studies for Pegtibatinase and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT03406611

    Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)

    Not yet reported, Not yet reported Travere Therapeutics, Inc. 39 participants Est. completion 2027-07 12 sites Stand-alone
    Other conditions: Homocystinuria
    View official trial listing →
  • Recruiting NCT NCT06247085

    Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment

    Not yet reported Travere Therapeutics, Inc. 70 participants Est. completion 2027-09 52 sites Stand-alone
    Other conditions: Homocystinuria
    View official trial listing →
  • Enrolling by invitation NCT NCT06431893

    A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)

    Not yet reported Travere Therapeutics, Inc. 100 participants Est. completion 2030-08 52 sites Stand-alone
    Other conditions: Homocystinuria
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Pegtibatinase, OT-058, TVT-058

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.